Eisei Hoshiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eisei Hoshiyama has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- George Imataka
Department of Pediatrics, Dokkyo Medical University, Mibu, Japan, Japan
3 shared publications - Hideaki Shiraishi
Department of Pediatrics, Dokkyo Medical University, Japan
3 shared publications - Kei Ogino
Division of Pediatric Surgery, Department of Upper Gastrointestinal Surgery, Dokkyo Medical University, Japan
3 shared publications - Masatoshi Uchida
Department of Emergency and Critical Care Medicine Dokkyo Medical University Mibu Japan
3 shared publications - Shigeko Kuwashima
Department of Radiology, Dokkyo Medical University, Japan
3 shared publications - Katsuhiko Naruse
Department of Obstetrics and Gynecology, Dokkyo Medical University, Tochigi, Japan
2 shared publications
Latest Publications
- 13 April 2026
- Published by Wiley in Neurology and Clinical Neuroscience
First‐Line Benzodiazepine Treatment for Convulsive Status Epilepticus in Adults: A Systematic Review and Meta‐Analysis
Convulsive status epilepticus (CSE) is a life‐threatening neurological emergency that requires prompt intervention. While several benzodiazepines are available as first‐line treatments, the optimal choice among them remains unclear. Therefore, we conducted a systematic review and meta‐analysis to evaluate the comparative effectiveness of these benzodiazepines for CSE. We conducted a comprehensive literature search of MEDLINE, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. We included randomized controlled trials involving adult patients with CSE who received benzodiazepines as first‐line treatment. Prehospital studies were also considered eligible. Two reviewers independently screened the studies and extracted relevant data. The outcomes were seizure termination, mortality, intubation, favorable neurological outcomes, seizure recurrence, and duration of hospitalization. Risk ratios (RRs) with 95% confidence intervals were calculated using a random‐effects model with inverse variance weighting. Among 3478 studies screened, three randomized controlled trials met the inclusion criteria: two comparing intravenous lorazepam with intravenous diazepam, and one comparing intramuscular midazolam with intravenous lorazepam. Intravenous lorazepam was associated with a higher seizure termination rate (RR 1.24, 95% CI: 1.03–1.49) to intravenous diazepam without an increase in adverse outcomes. Similarly, intramuscular midazolam was associated with higher seizure termination rates than intravenous lorazepam in prehospital settings (RR 1.16, 95% CI: 1.06–1.27). The present study demonstrated that intravenous lorazepam is more effective than intravenous diazepam. Furthermore, intramuscular midazolam may be more associated with higher seizure termination rates than intravenous lorazepam. Further evidence is needed to clarify the efficacy of intravenous lorazepam and both intravenous and intramuscular midazolam in adult patients.
- 13 April 2026
- Published by Wiley in Neurology and Clinical Neuroscience
First‐Line Benzodiazepine Treatment for Convulsive Status Epilepticus in Adults: A Systematic Review and Meta‐Analysis
Convulsive status epilepticus (CSE) is a life‐threatening neurological emergency that requires prompt intervention. While several benzodiazepines are available as first‐line treatments, the optimal choice among them remains unclear. Therefore, we conducted a systematic review and meta‐analysis to evaluate the comparative effectiveness of these benzodiazepines for CSE. We conducted a comprehensive literature search of MEDLINE, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. We included randomized controlled trials involving adult patients with CSE who received benzodiazepines as first‐line treatment. Prehospital studies were also considered eligible. Two reviewers independently screened the studies and extracted relevant data. The outcomes were seizure termination, mortality, intubation, favorable neurological outcomes, seizure recurrence, and duration of hospitalization. Risk ratios (RRs) with 95% confidence intervals were calculated using a random‐effects model with inverse variance weighting. Among 3478 studies screened, three randomized controlled trials met the inclusion criteria: two comparing intravenous lorazepam with intravenous diazepam, and one comparing intramuscular midazolam with intravenous lorazepam. Intravenous lorazepam was associated with a higher seizure termination rate (RR 1.24, 95% CI: 1.03–1.49) to intravenous diazepam without an increase in adverse outcomes. Similarly, intramuscular midazolam was associated with higher seizure termination rates than intravenous lorazepam in prehospital settings (RR 1.16, 95% CI: 1.06–1.27). The present study demonstrated that intravenous lorazepam is more effective than intravenous diazepam. Furthermore, intramuscular midazolam may be more associated with higher seizure termination rates than intravenous lorazepam. Further evidence is needed to clarify the efficacy of intravenous lorazepam and both intravenous and intramuscular midazolam in adult patients.
- 20 March 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Non‐Invasive Versus Invasive Ventilation for Acute Respiratory Failure in Neuromuscular Diseases: A Systematic Scoping Review
Acute respiratory failure is the most common life‐threatening complication of neuromuscular disease. Ventilatory support using invasive or non‐invasive methods is often required. However, the most effective form of support for patients with neuromuscular diseases and acute respiratory failure remains unclear. This review summarizes the existing literature on the efficacy of non‐invasive ventilation compared with invasive ventilation as first‐line support for this population. A systematic search was conducted in PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi for articles published until July 2024. Two reviewers independently screened studies for eligibility, assessed methodological quality, and extracted relevant data. Of 3758 studies identified, three observational studies met the inclusion criteria, encompassing 338 patients. Among them, 130 received non‐invasive ventilation and 208 received invasive ventilation. Due to variability in populations, interventions, and reported outcomes, data were summarized descriptively. Mortality rate was lower in patients receiving non‐invasive ventilation, with reported rates from 0% to 14%, compared with 16% to 57% in the invasive ventilation group. Length of intensive care unit stay and duration of ventilation were shorter in the non‐invasive ventilation group, ranging from 7 to 13.6 days and from 4 to 15.7 days, respectively, compared with 13 to 47.1 days and 9 to 21.7 days in the invasive ventilation group. Although current evidence is limited, findings suggest non‐invasive ventilation may be a viable alternative to invasive ventilation in selected patients. Successful ventilatory support should be tailored to each patient's condition, including bulbar dysfunction, progressive symptoms, or severe carbon dioxide retention.
- 20 March 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Non‐Invasive Versus Invasive Ventilation for Acute Respiratory Failure in Neuromuscular Diseases: A Systematic Scoping Review
Acute respiratory failure is the most common life‐threatening complication of neuromuscular disease. Ventilatory support using invasive or non‐invasive methods is often required. However, the most effective form of support for patients with neuromuscular diseases and acute respiratory failure remains unclear. This review summarizes the existing literature on the efficacy of non‐invasive ventilation compared with invasive ventilation as first‐line support for this population. A systematic search was conducted in PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi for articles published until July 2024. Two reviewers independently screened studies for eligibility, assessed methodological quality, and extracted relevant data. Of 3758 studies identified, three observational studies met the inclusion criteria, encompassing 338 patients. Among them, 130 received non‐invasive ventilation and 208 received invasive ventilation. Due to variability in populations, interventions, and reported outcomes, data were summarized descriptively. Mortality rate was lower in patients receiving non‐invasive ventilation, with reported rates from 0% to 14%, compared with 16% to 57% in the invasive ventilation group. Length of intensive care unit stay and duration of ventilation were shorter in the non‐invasive ventilation group, ranging from 7 to 13.6 days and from 4 to 15.7 days, respectively, compared with 13 to 47.1 days and 9 to 21.7 days in the invasive ventilation group. Although current evidence is limited, findings suggest non‐invasive ventilation may be a viable alternative to invasive ventilation in selected patients. Successful ventilatory support should be tailored to each patient's condition, including bulbar dysfunction, progressive symptoms, or severe carbon dioxide retention.
- Open Access
- 19 August 2025
- Published by MDPI AG in Preprints.org
Atypical Manifestations of Rett Syndrome: Macrocephaly and Hyperostosis Frontalis Interna in a Female Patient
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the MECP2 gene on the X chromosome, primarily affecting females. It is characterized by developmental regression, stereotypic hand movements, seizures, and microcephaly due to decelerated head growth. However, atypical presentations, such as macrocephaly and hyperostosis frontalis interna (HFI), are rarely reported. HFI, defined as abnormal thickening of the frontal bone, is uncommon in pediatric populations and is often linked to metabolic disturbances, hormonal imbalances, or prolonged anti-seizure medication (ASM) use. We report the case of a 16-year-old girl with genetically confirmed Rett syndrome who presented with macrocephaly (+2.5 SD) and HFI. Genetic testing identified a pathogenic MECP2 mutation (c.882C>T, Arg270Stop), confirming the diagnosis. The patient’s early development was normal until 18 months, when developmental regression occurred, including loss of speech, impaired social interactions, and stereotypic hand movements. She was also diagnosed with central precocious puberty at age 9, treated with leuprorelin acetate for three years, during which her growth in height ceased. By age 16, her height was -2.6 SD. Brain MRI revealed thickening of the frontal bone and enlarged frontal sinuses, consistent with HFI. She experienced intractable epilepsy managed with multiple ASMs. Reduction in ASM doses improved dystonia but led to seizure recurrence. Additional evaluations revealed mild osteopenia and altered hormonal profiles, suggesting systemic effects of MECP2 dysfunction. This case highlights the expanded phenotypic spectrum of Rett syndrome, emphasizing the impact of MECP2 mutations on cranial growth and bone metabolism. Hormonal dysregulation and ASM use may contribute to these anomalies. Comprehensive evaluation and genetic testing are critical for differentiating Rett syndrome from overlapping conditions. A multidisciplinary approach is essential to manage rare manifestations and improve personalized care strategies.
- 19 August 2025
- Published by MDPI AG in Preprints.org
Open AccessAtypical Manifestations of Rett Syndrome: Macrocephaly and Hyperostosis Frontalis Interna in a Female Patient
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the MECP2 gene on the X chromosome, primarily affecting females. It is characterized by developmental regression, stereotypic hand movements, seizures, and microcephaly due to decelerated head growth. However, atypical presentations, such as macrocephaly and hyperostosis frontalis interna (HFI), are rarely reported. HFI, defined as abnormal thickening of the frontal bone, is uncommon in pediatric populations and is often linked to metabolic disturbances, hormonal imbalances, or prolonged anti-seizure medication (ASM) use. We report the case of a 16-year-old girl with genetically confirmed Rett syndrome who presented with macrocephaly (+2.5 SD) and HFI. Genetic testing identified a pathogenic MECP2 mutation (c.882C>T, Arg270Stop), confirming the diagnosis. The patient’s early development was normal until 18 months, when developmental regression occurred, including loss of speech, impaired social interactions, and stereotypic hand movements. She was also diagnosed with central precocious puberty at age 9, treated with leuprorelin acetate for three years, during which her growth in height ceased. By age 16, her height was -2.6 SD. Brain MRI revealed thickening of the frontal bone and enlarged frontal sinuses, consistent with HFI. She experienced intractable epilepsy managed with multiple ASMs. Reduction in ASM doses improved dystonia but led to seizure recurrence. Additional evaluations revealed mild osteopenia and altered hormonal profiles, suggesting systemic effects of MECP2 dysfunction. This case highlights the expanded phenotypic spectrum of Rett syndrome, emphasizing the impact of MECP2 mutations on cranial growth and bone metabolism. Hormonal dysregulation and ASM use may contribute to these anomalies. Comprehensive evaluation and genetic testing are critical for differentiating Rett syndrome from overlapping conditions. A multidisciplinary approach is essential to manage rare manifestations and improve personalized care strategies.
- Open Access
- 17 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5071
Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been no approved medical therapy specifically aimed at achieving tumor shrinkage or regression. Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection. Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1. This review highlights the pathophysiology of NF1 and the therapeutic role of MEK inhibitors and presents a detailed case study of a patient treated with selumetinib, a novel MEK inhibitor. While the therapeutic potential of selumetinib has been demonstrated in preclinical and clinical studies, including those involving Japanese patients, this review aims to evaluate its application in real-world clinical practice. A comprehensive discussion of the case study provides insights into the efficacy, safety, and clinical challenges associated with selumetinib treatment, offering valuable perspectives for its use in managing NF1.
- 17 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5071
Open AccessNeurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been no approved medical therapy specifically aimed at achieving tumor shrinkage or regression. Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection. Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1. This review highlights the pathophysiology of NF1 and the therapeutic role of MEK inhibitors and presents a detailed case study of a patient treated with selumetinib, a novel MEK inhibitor. While the therapeutic potential of selumetinib has been demonstrated in preclinical and clinical studies, including those involving Japanese patients, this review aims to evaluate its application in real-world clinical practice. A comprehensive discussion of the case study provides insights into the efficacy, safety, and clinical challenges associated with selumetinib treatment, offering valuable perspectives for its use in managing NF1.
- Open Access
- 9 June 2025
- Published by MDPI AG in Preprints.org
Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy
Neurofibromatosis Type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been no approved medical therapy specifically aimed at achieving tumor shrinkage or regression. Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection. Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1. This review highlights the pathophysiology of NF1, the therapeutic role of MEK inhibitors, and presents a detailed case study of a patient treated with selumetinib, a novel MEK inhibitor. While the therapeutic potential of selumetinib has been demonstrated in preclinical and clinical studies, including those involving Japanese patients, this review aims to evaluate its application in real-world clinical practice. A comprehensive discussion of the case study provides insights into the efficacy, safety, and clinical challenges associated with selumetinib treatment, offering valuable perspectives for its use in managing NF1.
- 9 June 2025
- Published by MDPI AG in Preprints.org
Open AccessNeurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy
Neurofibromatosis Type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been no approved medical therapy specifically aimed at achieving tumor shrinkage or regression. Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection. Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1. This review highlights the pathophysiology of NF1, the therapeutic role of MEK inhibitors, and presents a detailed case study of a patient treated with selumetinib, a novel MEK inhibitor. While the therapeutic potential of selumetinib has been demonstrated in preclinical and clinical studies, including those involving Japanese patients, this review aims to evaluate its application in real-world clinical practice. A comprehensive discussion of the case study provides insights into the efficacy, safety, and clinical challenges associated with selumetinib treatment, offering valuable perspectives for its use in managing NF1.
- Open Access
- 7 January 2022
- Published by Wiley in Acute Medicine & Surgery
- Vol. 9 (1) , e717
Phenytoin versus other antiepileptic drugs as treatments for status epilepticus in adults: a systematic review and meta‐analysis
Aim: Status epilepticus (SE) is a life‐threatening neurological emergency. There is insufficient evidence regarding which antiepileptic therapy is most effective in patients with benzodiazepine‐refractory convulsive SE. Therefore, this study aimed to evaluate intravenous phenytoin (PHT) and other intravenous antiepileptic medications for SE.Methods: We searched PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi for published randomized controlled trials (RCTs) in humans up to August 2019. We compared outcomes between intravenous PHT and other intravenous medications. The important primary composite outcomes were the successful clinical cessation of seizures, mortality, and neurological outcomes at discharge. The reliability of the level of evidence for each outcome was compared using the Grading of Recommendations Assessment, Development, and Evaluation approach.Results: A total of 1,103 studies were identified from the databases, and 10 RCTs were included in the analysis. The ratio of successful clinical seizure cessation was significantly lower (risk ratio [RR] 0.89; 95% confidence interval [CI], 0.82–0.97) for patients treated with intravenous PHT than with other medications. When we compared mortality and neurological outcomes at discharge, we observed no significant differences between patients treated with PHT and those treated with other medications. The RRs were 1.07 (95% CI, 0.55–2.08) and 0.91 (95% CI, 0.72–1.15) for mortality and neurological outcomes at discharge, respectively.Conclusions: Our findings showed that intravenous PHT was significantly inferior to other medications in terms of the cessation of seizures. No significant differences were observed in mortality or neurological outcomes between PHT and other medications.
- 7 January 2022
- Published by Wiley in Acute Medicine & Surgery
- Vol. 9 (1) , e717
Open AccessPhenytoin versus other antiepileptic drugs as treatments for status epilepticus in adults: a systematic review and meta‐analysis
Aim: Status epilepticus (SE) is a life‐threatening neurological emergency. There is insufficient evidence regarding which antiepileptic therapy is most effective in patients with benzodiazepine‐refractory convulsive SE. Therefore, this study aimed to evaluate intravenous phenytoin (PHT) and other intravenous antiepileptic medications for SE.Methods: We searched PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi for published randomized controlled trials (RCTs) in humans up to August 2019. We compared outcomes between intravenous PHT and other intravenous medications. The important primary composite outcomes were the successful clinical cessation of seizures, mortality, and neurological outcomes at discharge. The reliability of the level of evidence for each outcome was compared using the Grading of Recommendations Assessment, Development, and Evaluation approach.Results: A total of 1,103 studies were identified from the databases, and 10 RCTs were included in the analysis. The ratio of successful clinical seizure cessation was significantly lower (risk ratio [RR] 0.89; 95% confidence interval [CI], 0.82–0.97) for patients treated with intravenous PHT than with other medications. When we compared mortality and neurological outcomes at discharge, we observed no significant differences between patients treated with PHT and those treated with other medications. The RRs were 1.07 (95% CI, 0.55–2.08) and 0.91 (95% CI, 0.72–1.15) for mortality and neurological outcomes at discharge, respectively.Conclusions: Our findings showed that intravenous PHT was significantly inferior to other medications in terms of the cessation of seizures. No significant differences were observed in mortality or neurological outcomes between PHT and other medications.